Review article: Yeast as probiotics - Saccharomyces boulardii

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 6, 2007, Pages 767-778

  Czerucka, D ^a   Piche, T ^a,b   Rampal, P ^c  

^a INSERM   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c Centre Hospitalier Princesse Grace   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; METRONIDAZOLE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; VANCOMYCIN;

ACUTE DIARRHEA; AIDS RELATED COMPLEX; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BIFIDOBACTERIUM BIFIDUM; CANDIDA ALBICANS; CANDIDA TROPICALIS; DIARRHEA; DRUG RESEARCH; ENTERIC FEEDING; ENTERITIS; ENTEROTOXIGENIC ESCHERICHIA COLI; FREEZE DRYING; FUNGUS ISOLATION; GENE OVEREXPRESSION; HUMAN; INFECTION PREVENTION; INFECTIOUS DIARRHEA; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; MEDLINE; MOLECULAR PHYLOGENY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; REFERENCE DATABASE; REVIEW; SACCHAROMYCES BOULARDII; SALMONELLA TYPHIMURIUM; SPECIES COMPARISON; THERAPY EFFECT; TORULOPSIS GLABRATA; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; DIARRHEA; DOUBLE-BLIND METHOD; HUMANS; PROBIOTICS; SACCHAROMYCES; TREATMENT OUTCOME;

EID: 34548303882     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03442.x     Document Type: Review

References (77)

1. Havenaar R, Huis in't Veld JHJ. Probiotics: a general view. In : Wood B, ed. The Lactic Acid Bacteria in Health and Disease, London, UK : Elsevier Applied Science, 1992 : 209 24.
2. Metchnikoff E. The Prolongation of Life. London, UK : Heinemann, 1907.
3. Clancy R. Immunobiotics and the probiotic evolution. FEMS Immunol Med Microbiol 2003 38 : 9 12.
4. Sazawal S, Hiremath G, Dhingra U, et al. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomized, placebo-controlled trials. Lancet Inf Dis 2006 6 : 374 82.
5. Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol 1996 430 : 435.
6. Giuliano M, Barza M, Jacobus NV, et al. Effect of broad-spectrum parenteral antibiotics on composition of intestinal microflora of humans. Antimicrob Agents Chemother 1987 31 : 202 6.
7. Salyers AA, Gupta A, Wang Y. Human intestinal bacteria as reservoirs for antibiotic resistance genes. Trends Microbiol 2004 12 : 412 6.
8. Mathur S, Singh R. Antibiotic resistance in food lactic acid bacteria: a review. Int J Food Microbiol 2005 105 : 281 95.
9. Temmerman R, Pot B, Huys G, Swings J. Identification and antibiotic susceptibility of bacterial isolates from probiotic products. Int J Food Microbiol 2003 81 : 1 10.
10. Hamann L, El-Samalouti V, Ulmer AJ, et al. Components of gut bacteria as immunomodulators. Int J Food Microbiol 1998 41 : 141 54.
11. Cid VJ, Duran A, Del Rey F, et al. Molecular basis of cell integrity and morphogenesis in Saccharomyces cerevisiae. Microbiol Rev 1995 59 : 345 86.
12. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002 20 : 197 216.
13. McFarland LV. Saccharomyces boulardii is not Saccharomyces cerevisiae. Clin Infect Dis 1996 22 : 200 1.
14. Cardinali G, Martini A. Electrophoretic karyotypes of authentic strains of the sensu stricto group of the genus Saccharomyces. Int J Syst Bacteriol 1994 44 : 791 7.
15. Vaughan-Martini A. Reflections on the classification of yeasts for different end-users in biotechnology, ecology and medicine. Int Microbiol 2003 6 : 175 82.
16. Mitterdorfer G, Mayer HK, Kneifel W, et al. Clustering of Saccharomyces boulardii strains within the species S. cerevisiae using molecular typing techniques. J Appl Microbiol 2002 93 : 521 30.
17. Edwards-Ingram L, Gitsham P, Burton P, et al. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl Environ Microbiol 2007 73 : 2458 67.
18. Hennequin C, Thierry A, Richard GF, et al. Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J Clin Microbiol 2001 39 : 551 9.
19. Fietto JLR, Araujo RS, Valadao FN, et al. Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii. Can J Microbiol 2004 50 : 615 21.
20. Bléhaut H, Massot J, Elmer GW, et al. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos 1989 10 : 353 64.
21. Elmer GW, McFarland LV, Surawicz CM, et al. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 1999 13 : 1663 8.
22. Bergogne-Bérézin E. Impact écologique de l'antibiothérapie. Place des microorganismes de substitution dans le contrôle des diarrhées et colites associées aux antibiotiques. Presse Méd 1995 24 : 145 56.
23. Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000 19 : 16 20.
24. Perapoch J, Planes AM, Querol A, et al. Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with Ultra-Levura. Eur J Clin Microbiol Infect Dis 2000 19 : 468 70.
25. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989 96 : 981 8.
26. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of β-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995 90 : 439 48.
27. Adam P. Essais cliniques controlés en double insu de l'ultra-levure lyophilisée (étude multicentrique par 25 médecins de 388 cas). Méd Chir Dig 1976 5 : 401 6.
28. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in children: randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005 21 : 583 90.
29. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhea: meta-analysis. BMJ 2002 324 : 1 6.
30. Beaugerie L, Flahault A, Barbut F, et al. Antibiotic-associated diarrhoea and Clostridium difficile in the community. Aliment Pharmacol Ther 2003 17 : 905 12.
31. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994 271 : 1913 8.
32. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000 31 : 1012 7.
33. Sanders JW, Tribble DR. Diarrhea in the returned traveller. Curr Gastroenterol Rep 2001 3 : 304 14.
34. Kollaritsch H, Holst H, Grobara P, et al. Prophylaxis of traveller's diarrhoea with Saccharomyces boulardii: results of a placebo-controlled double-blind study. Fortschr Med 1993 111 : 152 6.
35. McFarland L. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 2007 5 : 97 105.
36. Szajewska H, Ruszczynski M, Radzikowski M. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized trials. J Pediatr 2006 149 : 367 72.
37. Kurugol Z, Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhea. Acta Pediatr 2005 94 : 44 7.
38. Villarruel G, Rubio DM, Lopez F, et al. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Pediatr 2007 96 : 538 41.
39. Billoo AG, memon MA, Khaskheli SA, et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhea. World J Gastroenterol 2006 28 : 4557 60.
40. Tempe JD, Steidel AL, Bléhaut H, et al. Prévention par Saccharomyces boulardii des diarrhées de l'alimentation entérale à debit continu. Sem Hop Paris 1983 59 : 1409 12.
41. Schlotterer M, Bernasconi P, Lebreton F, et al. Intérêt de Saccharomyces boulardii dans la tolerance digestive de la nutrition entérale à debit continu chez le brulé. Nutr Clin Metabol 1987 1 : 31 4.
42. Bleichner G, Blehaut H, Mentec H, et al. Saccharomyces boulardii prevents diarrhea in critically-ill tube-fed patients. Intensive Care Med 1997 23 : 517 23.
43. Saint-Marc T, Rosello-Prats L, Touraine JL. Efficacité de Saccharomyces boulardii dans le traitement du SIDA. Ann Med Int 1991 142 : 64 5.
44. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. Z Gastroenterol 1993 31 : 129 34.
45. Guslandi M, Mezzi G, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000 45 : 1462 4.
46. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003 15 : 697 8.
47. Maupas JL, Champemont P, Delforge M. Treatment of irritable bowel syndrome with Saccharomyces boulardii: a double-blind, placebo-controlled study. Med Chir Dig 1983 12 : 77 9.
48. Czerucka D, Rampal P. Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 2002 4 : 733 9.
49. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993 104 : 1108 15.
50. Castagliuolo I, Lamont JT, Nikulasson ST, et al. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 1996 64 : 5225 32.
51. Chen X, Kokkotou EG, Mustafa N, et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo, and protects against Clostridium difficile toxin-A induced enteritis. JBC 2006 281 : 24449 59.
52. Brandão RL, Castro IM, Bambirra EA, et al. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microbiol 1998 64 : 564 8.
53. Vidon N, Huchet B, Rambaud JC. Influence de Saccharomyces boulardii sur la sécrétion jéjunale induite chez le rat par la toxine cholérique. Gastroentérol Clin Biol 1986 10 : 13 6.
54. Czerucka D, Roux I, Rampal P. Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′, 5′-cyclic monophosphate induction in intestinal cells. Gastroenterology 1994 106 : 65 72.
55. - secretion in T84 cells. Dig Dis Sci 1999 44 : 2359 68.
56. Buts JP, Dekeyser N, Stilmant C, et al. Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatric Res 2006 60 : 24 9.
57. Czerucka D, Dahan S, Mograbi B, et al. Saccharomyces boulardii preserves the barrier function and modulates the transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Inf Immun 2000 68 : 5998 6004.
58. Dahan S, Dalmasso G, Imbert V, et al. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signalling pathways in T84 cells. Inf Immun 2003 71 : 766 73.
59. Dalmasso G, Loubat A, Dahan S, et al. Saccharomyces boulardii prevents TNF-α-induced apoptosis in EHEC-infected T84 cells. Res Microbiol 2006 157 : 456 66.
60. Gedek BR. Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 1999 42 : 261 4.
61. Tasteyre A, Barc MC, Karjalainen T, et al. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb Pathog 2002 32 : 219 25.
62. Qamar A, Aboudola S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001 69 : 2762 5.
63. Buts JP, Bernasconi P, Vaerman JP, et al. Stimulation of secretory IgA and secretory component of immunoglobulins in the small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 1990 35 : 251 6.
64. Buts JP, Bernasconi P, Van Craynest MP, et al. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 1986 20 : 192 6.
65. Jahn HU, Ullrich R, Schneider T, et al. Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. Digestion 1996 57 : 95 104.
66. Buts JP, De Keyser N, Marandi S. Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Gut 1999 45 : 89 96.
67. Zaouche A, Loukil C, de Lagausie P, et al. Effects of oral Saccharomyces boulardii on bacterial overgrowth, translocation, and intestinal adaptation after small-bowel resection in rats. Scand J Gastroenterol 2000 35 : 160 5.
68. Buts JP, De Keyser N, De Raedemaeker L. Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res 1994 36 : 522 7.
69. Schneider SM, Girard-Pipau F, Filippi J, et al. Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J Gastroenterol 2005 11 : 6165 9.
70. + T cells induce or protect from chronic intestinal inflammation in C.B-17 scid mice. Int Immunol 1993 5 : 1461 71.
71. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995 182 : 1281 90.
72. Dalmasso G, Alexander G, Carlson H, et al. Saccharomyces boulardii prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Digestive Disease Week and the 106th Annual Meeting of the American Gastroenterology Association, 14-19 May 2005, Chicago, IL. Gastroenterology 2005 128 (Suppl. 4, Pt 2 A618.
73. Dalmasso G, Cottrez F, Imbert V, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 2006 131 : 1812 25.
74. Sougioultzis S, Simeonidis S, Bhaskar KR, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-κB-mediated IL-8 gene expression. BBRC 2006 34 : 69 76.
75. Segain JP, Raingeard de la Blétière D, Boureille A, et al. Butyrate inhibits inflammatory responses through NF-κB inhibition: implications for Crohn's disease. Gut 2000 47 : 397 403.
76. Lee SK, Kim HJ, Chi SG, et al. Saccharomyces boulardii activates expression of peroxisome proliferators-activated receptor-gamma in HT29 cells. Korean J Gastroenterol 2005 45 : 328 324.
77. Girard P, Pansart Y, Lorette I, et al. Dose-response relationship and mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhea in rats. Dig Dis Sci 2003 48 : 770 4.